Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Adverum Biotechnologies ( (ADVM) ) is now available.
On September 22, 2025, Adverum Biotechnologies announced the completion of screening for its pivotal Phase 3 ARTEMIS trial, evaluating the gene therapy Ixo-vec for wet age-related macular degeneration (AMD). The trial, which compares a single administration of Ixo-vec to regular aflibercept injections, is expected to achieve full enrollment by the fourth quarter of 2025, with topline data anticipated in the first quarter of 2027. This advancement positions Adverum as a leader in innovative ocular therapies, potentially transforming treatment paradigms for wet AMD and impacting patient care significantly.
The most recent analyst rating on (ADVM) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Adverum Biotechnologies stock, see the ADVM Stock Forecast page.
Spark’s Take on ADVM Stock
According to Spark, TipRanks’ AI Analyst, ADVM is a Neutral.
Adverum Biotechnologies’ overall stock score is primarily impacted by its financial performance challenges, with persistent losses and cash flow issues. While technical analysis shows some positive momentum, the negative valuation metrics due to ongoing losses weigh heavily on the score.
To see Spark’s full report on ADVM stock, click here.
More about Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company focused on developing gene therapy as a new standard of care for prevalent ocular diseases. The company aims to create functional cures to restore vision and prevent blindness, leveraging its proprietary intravitreal platform to develop durable, single-administration therapies that eliminate the need for frequent ocular injections.
Average Trading Volume: 165,795
Technical Sentiment Signal: Sell
Current Market Cap: $78.9M
See more data about ADVM stock on TipRanks’ Stock Analysis page.